Cabergoline vs Bromocriptine: Multicenter RCT
New England Journal of Medicine (1994)
Normalized prolactin in 83% vs 59% with bromocriptine, with significantly fewer adverse effects.
Cabergoline
Oral tablet (0.5mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
hormones
Long-acting ergot-derived dopamine D2 receptor agonist for hyperprolactinemia and prolactinomas. Highly effective at reducing prolactin, shrinking tumors, and restoring gonadal function. Once- or twice-weekly dosing.
Normalizes prolactin in >80% of patients
Shrinks prolactinomas in most patients
Twice-weekly dosing
Restores testosterone and fertility in men
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
High-affinity D2 receptor agonism on pituitary lactotrophs inhibits prolactin synthesis and secretion. Long half-life (63 to 69 hours) enables weekly dosing. Restores GnRH pulsatility suppressed by hyperprolactinemia.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Sex hormones
Adrenals & neurosteroids
Growth hormone / IGF-1
Thyroid hormones
Cardiovascular health
Insulin sensitivity
Liver & pancreas
Kidney function
Comprehensive Metabolic Panel (CMP)
Prostate health
Vitamins & minerals
Iron status
Complete Blood Count (CBC)
Clinical evidence
New England Journal of Medicine (1994)
Normalized prolactin in 83% vs 59% with bromocriptine, with significantly fewer adverse effects.
Safety profile
FAQ
Long-acting ergot-derived dopamine D2 receptor agonist for hyperprolactinemia and prolactinomas. Highly effective at reducing prolactin, shrinking tumors, and restoring gonadal function. Once- or twice-weekly dosing.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.